MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2022 International Congress

September 15-18, 2022. Madrid, Spain.

View by Title View Categories
Jump to:  View All • a b c [d] e f g h i j k l m n o p q r s t u v w x y z
  • Data-driven identification of distinct fronto-subcortical and cortical-posterior subtypes of cognitive decline in Parkinson’s disease

    M. Grothe, M. Labrador-Espinosa, S. Jesús, F. Roldán Lora, M. Aguilar Barberá, P. Pastor, S. Escalante Arroyo, B. Solano Vila, A. Cots Foraster, J. Ruiz Martínez, F. Carrillo Padilla, M. Pueyo Morlans, I. González Aramburu, J. Infante Ceberio, J. Hernández Vara, O. de Fábregues-Boixar, T. Deus Fonticoba, B. Pascual-Sedano, SG. Coppadis, P. Martínez-Martín, J. Kulisevsky, D. Santos-García, P. Mir (Seville, Spain)

  • DaTscan striatal binding ratio dynamics in mutations carriers at risk for Parkinson’s disease: A 2-year prospective study

    A. Droby, D. Atias, H. Lerman, RM. Hutchison, L. Yahimovich, J. Cedarbaum, E. Even Sapir, N. Giladi, A. Mirelman, A. Thaler (Tel Aviv, Israel)

  • DaxibotulinumtoxinA for Injection in Adults With Upper Limb Spasticity After Stroke or Traumatic Brain Injury: A Randomized Placebo-Controlled Study (JUNIPER)

    A. Patel, M. Munin, Z. Ayyoub, G. Francisco, T. Gross, R. Rubio, J. Kesslak (Lee's Summit, USA)

  • DBS Experience In A Pediatric Neurowilson Case

    S. Bozkaya Yilmaz, N. Olgaç Dündar, G. Basarir, P. Gencpinar, A. Ersen (Izmir, Turkey)

  • DBS for a patient with KMT2B-SHANK2 related dystonia

    L. Pan, G. Riboldi, A. Mogilner, C. Toro, S. Frucht (New York, USA)

  • DBS Targeting in a Neuromodulation Monitoring Unit – First 30 cases

    T. Sanger, J. Maclean, A. Tongol, J. Olaya, M. Liker (Orange, USA)

  • De novo mutation in TMEM151A and Paroxysmal Kinesigenic Dyskinesia

    T. Wirth, A. Méneret, N. Drouot, G. Rudolf, O. Lagha-Boukbiza, J. Chelly, C. Tranchant, A. Piton, E. Roze, M. Anheim (Strasbourg, France)

  • Decrease of striatal activity during the execution of a everyday-life motor habits in early Parkinson’s disease.

    P. Guida, M. Michiels, M. H Monje, J. Obeso, I. Obeso (Móstoles, Spain)

  • Deep behavioural analysis of zebrafish models of Parkinson’s disease

    TM. Tzotzolaki, J. Garcia Fernandez, F. de Santis, J. Terriente (Barcelona, Spain)

  • Deep brain stimulation and spinal cord stimulation for orthostatic tremor: a systematic review

    A. Billet, A. Boogers, W. Vandenberghe, B. Nuttin, T. Theys, M. Mc Laughlin, P. de Vloo (Leuven, Belgium)

  • Deep Brain Stimulation for Rare Neurodegenerative Diseases: Three-Center Experience

    N. Durmaz çelik, B. Samanci, G. Yalçın çakmaklı, A. Aksoy Gündoğdu, E. Erzurumluoğlu, Y. Samanci, M. Vural, B. Bilgiç, H. Hanağası, B. Elibol, S. özkan (Eskişehir, Turkey)

  • Deep Brain Stimulation in Generalized Dystonia Caused by PRKRA Mutation

    A. Falcone, C. Listik, S. Barbosa Casagrande, M. Torres, D. Boari Coelho, L. Augusto Teixeira, J. Papaterra Limongi, M. Jacobsen Teixeira, E. Reis Barbosa, R. Cury (Caçapava, Brazil)

  • Deep Brain Stimulation in Parkinson’s disease: Challenges of a young experience in southern Morocco

    Y. Naji, K. Saghir, M. Chraa, N. Kissani (Marrakech, Morocco)

  • Deep Brain Stimulation in Woodhouse Sakati Syndrome:A Single Institution Retrospect Analysis

    Y. Alkhodair, H. Alhodaif, F. Alotaibi, B. Boholega, A. Aldakheel (Riyadh, Saudi Arabia)

  • Deep brain stimulation increases descending inhibitory control in a patient with Parkinson´s disease and pain

    V. Mylius, J. Baars, G. Kägi, M. Krüger, D. de Andrade, F. Brugger (Valens, Switzerland)

  • Deep brain stimulation of the subthalamic nucleus under general vs local anesthesia

    S. Asriyants, A. Tomskiy, A. Gamaleya, A. Poddubskaya, A. Sedov, I. Pronin (Moscow, Russian Federation)

  • Deep learning applied to retinal OCT images to differentiate Parkinson’s disease patients from healthy controls

    M. Barrenechea, D. Romero-Bascones, A. Murueta-Goyena, JC. Gomez-Esteban, A. Alberdi, A. Erramuzpe, U. Ayala, I. Gabilondo (Mondragon, Spain)

  • Deep Learning Approaches for Recognition of Parkinson’s Disease Patients through Handwriting, Audio and Video Analysis

    JT. Li, Y. Qu, HL. Gao, Z. Min, ZJ. Mao, P. Xiao, X. Chen, LH. Wei, Q. Yu, Y X. Hao, Z. Xue, YJ. Xiong (Wuhan, China)

  • Deep learning to distinguish Parkinson’s from controls in video, without human-defined measures

    J. Yang, S. Williams, D. Hogg, J. Alty, S. Relton ()

  • Defining and restoring the underlying neural circuitry of hypersexuality in Parkinson’s Disease

    D. Mata-Marín, JA. Pineda-Pardo, M. Michiels, C. Pagge, C. Ammann, R. MARTíNEZ-FERNá[email protected], JA. Molina, L. Vela-Desojo, F. Alonso-Frech, JA. Obeso, I. Obeso (Móstoles, Spain)

  • Defining minimal clinically important differences in Huntington’s disease: An anchor-based approach

    J. Hamilton, J. Mills, G. Stebbins, J. Long, R. Fuller, S. Sathe, M. Roche, C. Sampaio (Princeton, USA)

  • Defining nomenclature and age cut off for Early Onset Parkinson’s Disease: Recommendations from the Early Onset Parkinson’s Disease Task Force.

    R. Mehanna, K. Smilowska, A. Merola, B. Zhang, B. Post, C. Marras, J. Fleisher, K. Kumar, M. Salari, O. Ross, R. Alcalay, T. Hatano, V. Mcconvey, Y-R. Wu, E-K. Tan, R. Savica (Houston, USA)

  • Delayed Osmotic Demyelination Syndrome- An Evolving Spectrum

    S. Garg, K. Shetty (Bengaluru, India)

  • Delayed post-stroke parkinsonism: description of two cases and possible mechanism

    T. Friedeman- Korn, M. Bauer, M. Abu Snineh, C. Weill, D. Arkadir (Jerusalem, Israel)

  • Deleterious GRN mutations: a new player in the etiology of Lewy body dementia

    P. Reho, S. Koga, Z. Shah, R. Chia, R. Rademakers, C. Dalgard, B. Boeve, T. Beach, D. Dickson, O. Ross, S. Scholz (Bethesda, USA)

  • Demographic and Regional Variation in All-Cause Mortality Rates among United States Medicare Beneficiaries with Parkinson’s Disease

    W. Aamodt, A. Willis, J. Farrar (Philadelphia, USA)

  • Demographics and Clinical Characteristics of Autosomal Dominant Spinocerebellar Ataxia in Canada: A Multicenter Study

    S. Alshimemeri, D. Aboalsamh, L. Zhou, S. Furtado, S. Kraft, V. Bruno, A. Duquette, B. Brais, O. Suchowersky, R. Munhoz, E. Slow (Riyadh, Saudi Arabia)

  • Depression and progression of motor symptoms in early stage of Parkinson’s disease

    YS. Hwang, SJ. Chung (Seoul, Republic of Korea)

  • Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612

    A. Espay, A. Ellenbogen, T. Gurevich, R. Case, L. Adar, T. Yardeni, L. Salin (Cincinnati, USA)

  • Design of a prodromal screening study for subtypes in Parkinson’s Disease

    E. Schaeffer (Kiel, Germany)

  • Design of the Remote Optimization Adjustment and Measurement for Deep Brain Stimulation (ROAM-DBS) Randomized Controlled Trial Using Decentralized Patient Monitoring

    T. Tomlinson, A. Gharabaghi, S. Groppa, L. Luo, H. Lu, M. Feldman, C. Luca, V. Marshall, A. Merola, L. Muñoz-Delgado, A. Schnitzler, L. Verhagen, B. Walter, C. Wu, S. Zauber, L. Zhang, B. Cheeran (Plano, USA)

  • Designing a multi-arm multi-stage trial for Parkinson’s

    M-L. Zeissler, M. Burnell, T. Barber, Y. Ben-Shlomo, R. Chapman, C. Clarke, C. Counsell, M. Edwards, R. Ellis-Doyle, C. Gonzales-Robles, A. Jewell, G. Mills, J. Rudiger, D. Salathiel, S. Whipps, A. Whone, T. Foltynie, C. Carroll, R. Barker, J. Carpenter (Plymouth, United Kingdom)

  • Detecting Parkinson’s Disease from body limb acceleration using machine learning and a frequency-domain analysis

    C. Cermeño-Silveira, JI. Godino-Llorente, A. Muñoz-Gonzalez, J. Perez-Sanchez, M. Gonzalez-Sanchez, F. Grandas-Perez, D. Torricelli (Madrid, Spain)

  • Detection and Analysis of Spatio-Temporal Variables of Parkinsonian Gait Using PODOSmart® Insoles

    E. Ziagkas, A. Loukovitis, S. Bostantjopoulou, Z. Katsarou, G. Grouios (Thessaloniki, Greece)

  • Detection of Parkinson’s Disease by Analysis of Smooth Pursuit Eye Movements and Machine Learning

    M. Bejani, E. Luque-Buzo, J. Gomez-García, A. Burlaka-Petrash, F. Grandas, J. Godino-Llorente (Madrid, Spain)

  • Detection of specific antigens in immune-mediated cerebellar ataxias

    A. Kudo, H. Yaguchi, M. Abe, A. Nagai, S. Shirai, I. Takahashi-Iwata, M. Matsushima, M. Watanabe, S. Hatakeyama, I. Yabe (Sapporo, Japan)

  • Deterioration in Wilson’s Disease despite treatment. Are the neuroimaging findings useful as prognostic factor?

    E. Urrea-Mendoza, S. Zaheer, F. Revilla (Greenville, USA)

  • Determinants of symptom severity in Parkinson’s disease: the International Vacation Survey

    J. Janssen Daalen, J. Hubbers, M. Sharifi Bonab, S. Mathur, D. Thijssen, B. Bloem, M. Meinders (Nijmegen, Netherlands)

  • Determination of glycine transporter 1 levels with [3H]-NFPS binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia

    I. Frouni, D. Bédard, E. Kim, S. Belliveau, C. Kwan, P. Huot (Montreal, Canada)

  • Determination of metabotropic glutamate receptor 2/3 distribution with [3H]-LY-341,495 in Parkinson’s disease patients with visual hallucinations

    D. Bedard, E. Kim, I. Frouni, P. Huot (Montreal, Canada)

  • Developing infrastructure for a multi-arm multi-stage trial in Parkinson’s

    M-L. Zeissler, J. Allison, D. Athauda, S. Bartolomeu Pires, G. Baxendale, K. Bhatia, D. Breen, R. Chapman, H. Collins, R. Croucher, R. Ellis-Doyle, C. Gonzales-Robles, F. Hudson, R. Khengar, P. Korlipara, C. Lambert, G. Mills, A. Morgan, H. Morris, J. Rudiger, M. Silverdale, S. Wonnacott, A. Yarnall, T. Foltynie, C. Carroll, S. Mullin (Plymouth, United Kingdom)

  • Developing New Insights Into Clinical and Genetic Features of PD – The Global Parkinson’s Genetics Program (GP2) Clinical Cohorts Working Group

    M. Richer, C. Towns, A. Martinez-Carrasco, J. Solle, A. Singleton, C. Blauwendraat, M. Tan, H. Iwaki, D. Vitale, Y. Song, M. Nalls, T. Antar, H. Morris (London, United Kingdom)

  • Developing zebrafish CRISPR/Cas9 knockout models of Parkinson’s Disease to identify novel therapeutic targets.

    J. García-Fernández, L. López-Blanch, M. Irimia, F. de Santis, J. Terriente (Badalona, Spain)

  • Development and validation of clinical scales for defining RBD severity in participants of the North American Prodromal Synucleinopathy (NAPS) consortium

    A. Busicescu (Phoenix, USA)

  • Development of a Novel Questionnaire on Women’s Health to Understand Its Role in Parkinson’s Disease Development and Progression

    S. Rao, N. Gutierrez, A. Naito, K. Ghosh, B. Lapin, M. de Leon, I. Mata (Cleveland, USA)

  • Development of a patient journey map for people living with cervical dystonia

    M. Benson, A. Albanese, K. Bhatia, P. Cavillon, L. Cuffe, K. König, C. Reinhard, H. Graessner (Brussels, Belgium)

  • Development of a quality-of-life (QoL) questionnaire for hereditary spastic paraplegia (HSP) patients and caregivers.

    J. Malina, B. Schröder, E. Hüßler, T. Kühl, S. Klebe (Essen, Germany)

  • Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies

    R. Barbour, A. Elmaarouf, L. Louie, S. Tam, C. Tourino, B. Campbell, G. Kinney, W. Zago (South San Francisco, USA)

  • Developmental Validity of the revised improved version of the Fragile X-associated Tremor Ataxia Syndrome Rating Scale (FXTAS-RS)

    M. Tosin, G. Stebbins, C. Goetz, R. Hagerman, D. Hessl, M. Zolecki, P. Todd, M. Leehey, D. Hall (Chicago, USA)

  • DHDDS and NUS1: A converging pathway and common phenotype

    L. Williams, J. Qiu, S. Waller, N. Elserafy, M. Tchan, P. Procopis, H. Sampaio, S. Mohammad, H. Morales-Briceño, V. Fung (Sydney, Australia)

  • Diagnosed and Drug-Treated Prevalence of Essential Tremor in Adult Patients: Retrospective Analyses of Two US Healthcare Claims Databases

    R. Saad, M. Markowitz, L. Gibbs, D. Fuller, W. Ni, R. Pahwa, K. Lyons, M. Baladi, J. Lin (Palo Alto, USA)

  • Diagnosed and Drug-Treated Prevalence of Essential Tremor in Pediatric Patients: Retrospective Analyses of Two US Healthcare Claims Databases

    R. Saad, M. Markowitz, L. Gibbs, D. F, W. Ni, R. Pahwa, K. Lyons, M. Baladi, J. Lin (Palo Alto, USA)

  • Diagnosis of Niemann-Pick type C disease: adult onset form

    AM. Diezma-Martin, MI. Morales-Casado, P. Lobato Casado, JC. Segundo Rodriguez, F. Muñoz Escudero, DD. Garcia Melendez, N. Lopez Ariztegui (Toledo, Spain)

  • Diagnostic accuracy of dopamine SPECT in degenerative parkinsonism compared to neuropathological diagnosis.

    A. Hastings, H. Morris, Z. Jaunmuktane, T. Warner, E. de Pablo-Fernandez (London, United Kingdom)

  • Diagnostic Accuracy of Parkinson’s disease: Where Do We Stand?

    S. Virameteekul (London, United Kingdom)

  • Diagnostic algorithm in recessive and sporadic early-onset ataxias

    D. Gasca Saldaña, C. Boll Woehrlen, N. Jaramillo, C. Alaez-Verson (Ciudad de México, Mexico)

  • Diagnostic Utility of I123-FP-CIT Single Photon Emission Computed Tomography for Patients with Clinically Uncertain Parkinsonian Syndrome

    R. Falconer, T. Hunter, E. Szabo, C. Brand (Alexandria, USA)

  • Diagnostic value of striatal [18F]-FP-DTBZ PET in Parkinson’s disease

    X. Liu, S. Liu, O. Barret, G. Tamagnan, H. Qiao, T. Song, C. Piu, J. Lu (Beijing, China)

  • Diagnostic yield for point mutation related SCAs through exome sequencing for undetermined ataxias

    JL. Pedroso, T. Silva, M. França Jr, O. Barsottini (São Paulo, Brazil)

  • DIFFERENCE IN MOTOR AND NONMOTOR SYMPTOMS BETWEEN YOUNG AND LATE ONSET PARKINSON`S DISEASE

    LH. Horvat, Z. Popovic, T. Gilman Kuric, I. Rajkovaca Latic, T. Mirosevic Zubonja, J. Kragujevic, S. Tomic ()

  • Differences between two cognitive assessment instruments used in Parkinson’s disease in Kyrgyzstan

    E. Zhunusova, C. Shambetova, A. Il'Yazova (Bishkek, Kyrgyzstan)

  • Differences in cognition and neuropsychiatric profiles between asymptomatic and symptomatic carriers of Huntington’s disease

    M. Turuelo (Barakaldo, Spain)

  • DIFFERENCES IN KINEMATIC AND SPATIO-TEMPORAL PARAMETERS ASSESSED BY INSTRUMENTED “TIMED UP AND GO” TEST BETWEEN IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS ASSOCIATED WITH PARKINSONISM AND PARKINSON’S DISEASE.

    G. Mostile, F. Contrafatto, R. Terranova, C. Terravecchia, A. Luca, M. Sinitò, G. Donzuso, CE. Cicero, G. Sciacca, A. Nicoletti, M. Zappia (Catania, Italy)

  • Different longitudinal manifestations in dopaminergic dysfunction in REM sleep behavior disorder

    P. Wu, H. Yu (Shanghai, China)

  • DIFFERENT PATTERNS OF ACUTE SACCADIC RESPONSES TO LEVODOPA CHALLENGE TEST IN DE NOVO PARKINSON’S DISEASE: POSSIBILE PROGNOSTIC IMPLICATIONS

    C. Terravecchia, G. Mostile, CG. Chisari, A. Luca, R. Terranova, G. Donzuso, CE. Cicero, G. Sciacca, A. Nicoletti, M. Zappia (Catania, Italy)

  • Differential proteomic analysis of plasma exosomes in Parkinson disease associated with mutations in the GBA gene

    T. Usenko, A. Bezrukova, K. Basharova, D. Kulabukhova, I. Miliukhina, E. Zakharova, S. Naryzhny, S. Pchelina (Gatchina, Russian Federation)

  • Differential temporal dynamics of axial and appendicular ataxia in SCA3

    R. Maas, S. Teerenstra, M. Lima, P. Pires, L. Pereira, J. van Gaalen, D. Timmann, J. Infante, C. Onyike, K. Bushara, H. Jacobi, K. Reetz, M. Santana, J. Ribeiro, J. Hübener-Schmid, J. de Vries, M. Synofzik, L. Schöls, H. Garcia-Moreno, P. Giunti, J. Faber, T. Klockgether, B. Vande Warrenburg (Nijmegen, Netherlands)

  • Diffusion MRI tractometry findings in Dystonia- A UK Biobank study

    C. Maciver, M. Wadon, G. Bailey, A. Schalkamp, C. Sandor, D. Jones, C. Tax, K. Peall (Cardiff, United Kingdom)

  • Diffusion-weighted imaging based free-water investigation in Parkinsonian disorders

    AKS. Shah, JS. Saini, MI. Ingalhalikar, SP. Prasad, PKP. Pal (Pune, India)

  • Digital Biomarkers for Deep Brain Stimulation Programming in PD

    C. Graef, A. Bocum, M. Ciocca, B. Seemungal, Y. Tai, S. Haar (London, United Kingdom)

  • Digital Sway Measures for Spinocerebellar Ataxia

    V. Shah, J. Mcnames, H. Casey, K. Floyd, R. Rodriguez-Labrada, J. Schmahmann, L. Rosenthal, S. Perlman, M. El Gohary, K. Sowalsky,, M. Mancini, L. Velázquez-Pérez, F. Horak, C. Gomez (Portland, USA)

  • Directional DBS – Early experiences with “Current steering” in India

    VM. Mathur, PD. Doshi, AA. Aundhkar, MB. Baldia, PW. Wadia (Mumbai, India)

  • Discrepancies in postural stability outcomes measured by computerized dynamic posturography and functional balance assessments in Parkinson’s Disease

    E. Doctor, R. Bliss, J. Kanaley (Columbia, USA)

  • Discrimination in Healthcare for Parkinsonism Across Sexual and Gender Minority Groups

    E. Bayram, K. Wyman-Chick, L. Damron, I. Litvan (La Jolla, USA)

  • Disease knowledge in males and females with Parkinson’s Disease and Related Disorders

    C. Selvadurai, E. Cournean, D. Costello, N. Prakash, B. Rodrigues (Farmington, USA)

  • Distinct amyloid-dependent patterns of nigral dopamine depletion in Lewy body diseases

    K. Baik, J. Cha, M. Park, Y. Lee, SW. Kang, SH. Yoon, H. Na, Y. Sohn, P. Lee (Seoul, Republic of Korea)

  • Distinct Patterns of Tremor Network Microstructure for Essential Tremor and Parkinson’s Disease

    T. Welton, A. Ong, S. Hartono, Y-C. Shih, A. Lee, E-K. Tan, L-L. Chan (Singapore, Singapore)

  • Distribution of rapid eye movement (REM) sleep without atonia (RWA) across the REM cycles.

    A. Dagay, S. Oz, SH. Katzav, D. Wasserman, N. Giladi, A. Mirelman (Netanya, Israel)

  • Diverse alteration of brain networking in PD with ICD-RBs

    YJ. Guo, CM. Chen, JR. Duann, MK. Lu, MH. Chang (Taichung, Taiwan)

  • DNA methylation differs between idiopathic Parkinson Disease and Healthy Control subjects in the Parkinson’s Progression Marker Initiative (PPMI) cohort

    P. Gonzalez-Latapi, B. Bustos, T. Simuni, S. Lubbe, D. Krainc (Chicago, USA)

  • DNMT1 level and global DNA methylation in CD45+ blood cells in Parkinson’s disease

    A. Lavrinova, A. Zhuravlev, I. Miliukhina, E. Belykh, A. Tyurin, O. Berkovich, S. Pchelina, A. Emelyanov (Gatchina, Russian Federation)

  • Do clinical neuropsychological tasks capture visuoperceptual deficits in culturally-diverse individuals with Parkinson’s disease and hallucinations?

    S. Adamo, M. Statucka, M. Cohn (Toronto, Canada)

  • Does aging influence eating behavior during COVID-19 pandemic in patients with Parkinson’s Disease in northeastern Mexico?

    C. López Botello, S. Castillo Torres, I. Estrada Bellmann, B. Chávez Luevanos (Monterrey, Mexico)

  • Does autosomal recessive Parkinson’s Disease behave as “Brain-first” subtype?

    B. Soydas-Turan, G. Yalcin-Cakmakli, B. Volkan-Salanci, E. Lay-Ergun, B. Elibol (Ankara, Turkey)

  • Does needle size matter in botulinum toxin injection? A crossover randomised controlled trial of microneedle in patients with hemifacial spasm

    S. Maytharakcheep, R. Bhidayasiri, O. Phokaewvarangkul (bangkok, Thailand)

  • Does Patients with Parkinson diseases have distinctive PD personality? An insight on the phenomenology of Parkinson’s Disease

    GB. Eow, K. Tan, HJ. Tan, HY. Ch'Ng, TS. Thannimalai, TH. Lee, TT. Lim, R. Bhidayasari, WY. Ooi, MY. Wong (George Town, Malaysia)

  • Dopa-responsive Combined Dystonia Due to ATP1A3 Gene Variant

    M. Soares, J. Parmera, M. Bezerra (São Paulo, Brazil)

  • Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel

    J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, S. Bataga, R. Neagoe, J. Szederjesi, B. Grigorescu, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmari (Targu Mures, Romania)

  • Dopamine neuron platform for screening molecular mechanisms and inhibitory drugs against alpha-synuclein aggregation

    S. Er, I. Hlushchuk, P. Chmielarz, A. Domanskyi, M. Airavaara (Helsinki, Finland)

  • Dopamine-independent cortical disinhibition in Parkinson’s disease

    C. Ammann, M. Dileone, C. Pagge, D. Mata-Marín, M. Matarrazzo, M. Monje, A. Sánchez-Ferro, B. Fernández-Rodríguez, C. Gasca-Salas, J. Máñez-Miró, R. Martínez-Fernández, L. Vela, F. Alonso-Frech, A. Oliviero, JA. Obeso, G. Foffani (Móstoles, Spain)

  • Dopaminergic Denervation as Predictors of Axial Dysfunction in Parkinson’s Disease

    J. Li, N. Phielipp (Irvine, USA)

  • Dopaminergic Denervation as Predictors of Falls in PD Patients

    J. Li, N. Phielipp (Irvine, USA)

  • Dopaminergic medication improves movement vigour in Parkinson’s but not the adaptation of movement speed to curvature

    L. Hickman, D. Fraser, J. Galea, J. Cook (Birmingham, United Kingdom)

  • Dopaminergic modulation of express reaching responses in Parkinson’s disease

    M. Gilchrist, R. Kozak, B. Corneil, P. Macdonald (London, Canada)

  • Dorsolateral nigral hyperintensity on 1.5 versus 3T susceptibility-weighted magnetic resonance imaging in neurodegenerative parkinsonism

    B. Heim, A. Grossauer, F. Krismer, W. Poewe, K. Seppi (Innsbruck, Austria)

  • Double trouble: Association of malignant melanoma with sporadic and genetic forms of Parkinson’s disease and asymptomatic carriers of related genes in the PPMI study.

    C. Koros, AM. Simitsi, A. Bougea, N. Papagiannakis, I. Pachi, A. Prentakis, R. Antonelou, A. Zahou, I. Beratis, E. Efthymiopoulou, E. Stanitsa, C. Chrysovitsanou, E. Angelopoulou, K. Lourentzos, V. Constantinides, M. Bozi, D. Papadimitriou, A. Bonakis, G. Paraskevas, C. Potagas, S. Papageorgiou, X. Trapali, M. Stamelou, L. Stefanis (Athens, Greece)

  • Dried blood and plasma spots for the measurement of neurofilament light chain and inflammatory cytokines in patients with REM sleep behaviour disorder

    B. Huxford, C. Simonet, L. Carbonell, A. Zirra, N. Vickaryous, A. Gill, A. Schrag, R. Dobson, A. Noyce (London, United Kingdom)

  • Drivers of burden over time in caregivers of patients with Parkinson’s disease and related disorders: Findings from a community-based clinical trial of outpatient palliative care

    A. Glickman, Z. Macchi, S. Sillau, M. Katz, S. Pantilat, B. Kluger (Aurora, USA)

  • Dual target deep brain stimulation for clinically complex tremor disorders: a single centre prospective study

    R. Heartshorne, J. Osman-Farah, A. Macerollo (Liverpool, United Kingdom)

  • Duration of continuous “Good On” intervals and number of motor fluctuations after treatment with IPX203 vs immediate-release carbidopa-levodopa in Parkinson’s disease patients with motor fluctuations.

    R. Hauser, H. Fernandez, J. Aldred, C. Singer, H. Shill, S. Factor, H. Visser, R. D'Souza (Tampa, USA)

  • DUtch PARkinson Cohort (DUPARC): Contrast Sensitivity and Retinal Changes in Early Parkinson’s Disease Patients

    C. Gillen, S. Zee, N. Jansonius, T. van Laar (Groningen, Netherlands)

  • Dynamic functional connectivity changes and striatal dopamine deficiency in Parkinson’s disease

    A. Asendorf, H. Theis, M. Tittgemeyer, L. Timmermann, G. Fink, A. Drzezga, M. Hoenig, T. van Eimeren (Cologne, Germany)

  • Dynamical modulations of low frequency deep brain stimulation on axial symptoms in Parkinson’s disease

    Y. Thenaisie, L. Comeliau, C. Varescon, L. Asboth, M. Castro, J. Bally, G. Courtine, J. Bloch, E. Martin Moraud (Lausanne, Switzerland)

  • Dyskinesia profiles after dose challenges with L-dopa vs L-dopa plus ropinirole: a pilot study

    S. Grigoriou, P. Odin, E. Espa, A. Cenci (Lund, Sweden)

  • Dysphagia and its relationship to medication intake in Parkinson’s disease

    B. Labeit, E. Berkovich, I. Claus, M. Roderigo, AL. Schwake, D. Izgelov, D. Mimrod, S. Ahring, S. Oeleberg, P. Muhle, V. Zentsch, F. Wenninger, S. Suntrup-Krueger, R. Dziewas, T. Warnecke (Muenster, Germany)

  • Dysphagia management in Parkinson’s patients during admission to Royal Berkshire Hospital(RBH),Reading,UK.

    M. Khwaja, G. Desai, J. Murphy, A. Chatterjee (Reading, United Kingdom)

  • Dystonia prior and after seeing a Neurologist at the Neurology department of Befelatanana University Hospital, Antananarivo, Madagascar

    NF. Rasaholiarison, JL. Rakotomanana, LA. Rajaonarison, F. Razafizandry, J. Razafimahefa, AD. Tehindrazanarivelo (Fianarantsoa, Madagascar)

  • DystoniaBoTXNet: A Deep Learning Platform for Predictive Outcome of Botulinum Toxin Treatment in Isolated Dystonia

    D. Yao, L. O'Flynn, K. Simonyan (Boston, USA)

  • Dystonic tremor: one symptom, different etiologies: About three cases

    S. Laroussi, S. Sakka, N. Bouattour, N. Farhat, S. Daoud, K. Moalla, H. Hadjkacem, M. Damak, C. Mhiri (Sfax, Tunisia)

Jump to:  View All • a b c [d] e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley